Why the study?
Should angiotensin-converting enzyme inhibitors and angiotensin receptor blockers be used in patients with or at risk of COVID-19?
Should angiotensin-converting enzyme inhibitors and angiotensin receptor blockers be used in patients with or at risk of COVID-19?
This Viewpoint discusses recommendations for ACEi and ARB use in the context of COVID-19 infection.
This Viewpoint discusses recommendations for angiotensin-converting enzyme inhibitor and angiotensin receptor blocker use in patients with or at risk of contracting coronavirus disease 2019 (COVID-19).
No takes yet. Share an insight, caveat, or question.
Bavishi et al. (2020) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: